As previously reported, BofA analyst Jason Gerberry upgraded United Therapeutics (UTHR) to Neutral from Underperform with an unchanged price ...

BofA upgraded United Therapeutics (UTHR) to Neutral from Underperform with a $314 price target Stay Ahead of the Market: Discover ...

Patterson is a registered nurse and executive director of a consulting firm that supports OPTN contracts.

Shares of Channel Therapeutics Corporation (CHRO) rocketed 61% on Thursday after the company entered into a definitive merger ...

Treatment options are limited for those with sudden liver failure and the condition has a death rate as high as 50%.

For the first time since 2016, I enjoyed time with friends and family without planning around dialysis treatments,” the patient said in a statement.

Regulus Therapeutics Inc.’s RGLS share price has surged by 5.41%, which has investors questioning if this is right time to sell.

They look like human organs, they work like human organs ... The Food and Drug Administration has given United Therapeutics ...